KIDS ORTHOPEDIATRICS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1425450 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.1%
TTM net income YoY25.7%
TTM EPS YoY27.6%
Revenue 3-yr CAGR23.0%
Net income 3-yr CAGR—
Margins
Gross margin73.8%
Operating margin-9.4%
Net margin-12.8%
FCF margin1.2%
EBITDA margin-0.8%
Returns
ROE-9.8%
ROA-6.8%
ROIC (approx.)-4.6%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets33.3%
Debt / equity0.30x
Current ratio4.55x
Interest coverage-2.70x
Cash quality & payout
Operating cash flow / net income-0.37x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $236.35M | $204.73M |
| Cost of revenue | $63.69M | $56.13M |
| Gross profit | $172.66M | $148.60M |
| R&D expense | $9.10M | $11.03M |
| SG&A expense | $119.83M | $102.79M |
| Operating income | -$39.24M | -$35.01M |
| Interest expense | $6.00M | $2.62M |
| Pretax income | -$39.19M | -$41.93M |
| Income tax | $460,000 | -$4.11M |
| Net income | -$39.65M | -$37.82M |
| EBITDA | -$18.12M | -$15.93M |
| EPS (basic) | -1.69 | -1.64 |
| EPS (diluted) | -1.69 | -1.64 |
| Weighted avg. shares (diluted) | 23.46M | 23.08M |
| Balance sheet | ||
| Cash & equivalents | $19.56M | $45.78M |
| Short-term investments | $41.30M | $25.01M |
| Receivables | $53.84M | $42.36M |
| Inventory | $133.79M | $117.00M |
| Current assets | $256.42M | $237.17M |
| PP&E, net | $49.55M | $50.60M |
| Goodwill | $109.27M | $93.84M |
| Intangibles | $64.80M | $64.43M |
| Total assets | $508.63M | $473.21M |
| Current liabilities | $46.20M | $33.96M |
| Short-term debt | $1.87M | $897,000 |
| Long-term debt | $99.82M | $72.96M |
| Total debt | $101.68M | $73.85M |
| Total liabilities | $162.03M | $118.64M |
| Shareholders' equity | $346.60M | $354.57M |
| Net debt | $82.13M | $28.08M |
| Shares outstanding | 25.09M | 24.22M |
| Cash flow statement | ||
| Operating cash flow | -$4.85M | -$27.05M |
| Capital expenditure | $11.11M | $14.26M |
| Free cash flow | -$15.96M | -$41.31M |
| Investing cash flow | -$43.63M | -$13.16M |
| Financing cash flow | $23.98M | $53.13M |
| Depreciation & amortization | $21.12M | $19.08M |
| Stock-based compensation | $17.78M | $13.55M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.